SUPER SOLID SUPERMAX Holding its ground well today. - Sellers depleting as BONUS is just around the corner.

Will trend higher as the Ex day for Bonus approaches.

Bonus Ex-Date 04 Sep 2020

HOLD.

Keep it up Teamrocket. Whatever he says the OPPOSITE happens.

2 factors to further boost Gloves Sector

1-Global cases pass 20m heading to 25 millions
---------------------------------
More than 23.1 million people have been diagnosed with COVID-19 around the world, and more than 14.91 million have recovered. At least 804,400 people have died, according to Johns Hopkins University.
India has had the highest number of daily new cases in the world for the last 18 days, with more than 50,000 new cases every day.
Korea Centers for Disease Control and Prevention (KCDC) has warned the country is on the brink of a nationwide outbreak following the highest daily number of coronavirus cases recorded since March.

2-Rubber glove shares will rise as oil prices fall again and play around $45 below per barrel
----------------------------------
Higher nitrile glove prices possible on costlier crude oil. Malaysian glove manufacturers may raise synthetic rubber or nitrile glove prices in anticipation of costlier raw materials
As the coronavirus ravages economies and cripples demand, European oil majors have made some uncomfortable admissions in recent months. Oil and gas worth billions of dollars might never be pumped out of the ground
High costs, low oil prices increasing financial risks for deepwater drillers.

Pharmaniaga bersedia botolkan vaksin COVID-19

23/08/2020

KUALA LUMPUR: Pharmaniaga Bhd bersedia untuk membuat perubahan yang diperlukan kepada kilang sedia ada yang akan membolehkan mereka menjalankan proses pembangunan pembotolan untuk vaksin COVID-19 apabila ia dibangunkan.

Pemangku Pengarah Urusannya, Mohamed Iqbal Abdul Rahman, berkata kumpulan telah membentangkan kepada Majlis Sains Negara mengenai pelan, kapasiti dan keupayaannya untuk tujuan berkenaan.

"Ini adalah sebahagian daripada pelan jangka pendek kumpulan untuk menangani keperluan mendesak kepada vaksin COVID-19," katanya.

Menteri Sains, Teknologi dan Inovasi Khairy Jamaluddin sebelum ini berkata, kerajaan bersetuju bahawa kemudahan yang dimiliki oleh Duopharma Biotech Bhd dan Pharmaniaga akan digunakan untuk pembotolan vaksin.

Khairy dilaporkan menjelaskan bahawa kedua-dua syarikat itu dipilih berikutan kedua-duanya berkaitan dengan kerajaan.

Duopharma dimiliki oleh Permodalan Nasional Bhd (PNB) dan Pharmaniaga dimiliki oleh Boustead Holdings Bhd, yang pada masa ini mempunyai kapasiti yang tidak digunakan yang dapat diarahkan untuk tujuan ini.

Mengenai perancangan kumpulan pada masa depan pula, Mohamed Iqbal berkata Pharmaniaga, syarikat farmaseutikal terbesar di Malaysia, dijangka mewujudkan kemudahan vaksin halal pertama di dunia, disasarkan siap pada 2022.

"Pada 2018, Pharmaniaga mengumumkan pelan untuk mendirikan kilang vaksin. Sejak itu, kami telah selesai menjalankan kajian terperinci yang diperlukan dan menjalin kerjasama dengan pengeluar vaksin antarabangsa," katanya.

Selain itu, Pharmaniaga mempunyai pelan jangka panjang untuk pertumbuhan mampan dan menetapkan enam teras strategik untuk memacu syarikat ke peringkat lebih tinggi.

Sebagai syarikat berkaitan kerajaan, Pharmaniaga komited untuk terus memberikan standard perkhidmatan tertinggi untuk membolehkan Kementerian Kesihatan memberi tumpuan kepada penyampaian penjagaan kesihatan, dengan Pharmaniaga sebagai rakan logistik pilihannya.

"Walaupun telah mendapat kontrak logistik dan pengedaran sehingga November 2024, kami berharap dengan rekod prestasi, infrastruktur yang siap, teknologi maklumat bersepadu dan yang paling penting, modal insan yang berpengalaman, akan menempatkan kami dengan baik untuk mendapatkan potensi lanjutan selepas tempoh ini," katanya.

BERNAMA

Pharmaniaga bersedia botolkan vaksin COVID-19

23/08/2020

KUALA LUMPUR: Pharmaniaga Bhd bersedia untuk membuat perubahan yang diperlukan kepada kilang sedia ada yang akan membolehkan mereka menjalankan proses pembangunan pembotolan untuk vaksin COVID-19 apabila ia dibangunkan.

Pemangku Pengarah Urusannya, Mohamed Iqbal Abdul Rahman, berkata kumpulan telah membentangkan kepada Majlis Sains Negara mengenai pelan, kapasiti dan keupayaannya untuk tujuan berkenaan.

"Ini adalah sebahagian daripada pelan jangka pendek kumpulan untuk menangani keperluan mendesak kepada vaksin COVID-19," katanya.

Menteri Sains, Teknologi dan Inovasi Khairy Jamaluddin sebelum ini berkata, kerajaan bersetuju bahawa kemudahan yang dimiliki oleh Duopharma Biotech Bhd dan Pharmaniaga akan digunakan untuk pembotolan vaksin.

Khairy dilaporkan menjelaskan bahawa kedua-dua syarikat itu dipilih berikutan kedua-duanya berkaitan dengan kerajaan.

Duopharma dimiliki oleh Permodalan Nasional Bhd (PNB) dan Pharmaniaga dimiliki oleh Boustead Holdings Bhd, yang pada masa ini mempunyai kapasiti yang tidak digunakan yang dapat diarahkan untuk tujuan ini.

Mengenai perancangan kumpulan pada masa depan pula, Mohamed Iqbal berkata Pharmaniaga, syarikat farmaseutikal terbesar di Malaysia, dijangka mewujudkan kemudahan vaksin halal pertama di dunia, disasarkan siap pada 2022.

"Pada 2018, Pharmaniaga mengumumkan pelan untuk mendirikan kilang vaksin. Sejak itu, kami telah selesai menjalankan kajian terperinci yang diperlukan dan menjalin kerjasama dengan pengeluar vaksin antarabangsa," katanya.

Selain itu, Pharmaniaga mempunyai pelan jangka panjang untuk pertumbuhan mampan dan menetapkan enam teras strategik untuk memacu syarikat ke peringkat lebih tinggi.

Sebagai syarikat berkaitan kerajaan, Pharmaniaga komited untuk terus memberikan standard perkhidmatan tertinggi untuk membolehkan Kementerian Kesihatan memberi tumpuan kepada penyampaian penjagaan kesihatan, dengan Pharmaniaga sebagai rakan logistik pilihannya.

"Walaupun telah mendapat kontrak logistik dan pengedaran sehingga November 2024, kami berharap dengan rekod prestasi, infrastruktur yang siap, teknologi maklumat bersepadu dan yang paling penting, modal insan yang berpengalaman, akan menempatkan kami dengan baik untuk mendapatkan potensi lanjutan selepas tempoh ini," katanya.

BERNAMA

Pharmaniaga bersedia botolkan vaksin COVID-19
Share 23/08/2020

KUALA LUMPUR: Pharmaniaga Bhd bersedia untuk membuat perubahan yang diperlukan kepada kilang sedia ada yang akan membolehkan mereka menjalankan proses pembangunan pembotolan untuk vaksin COVID-19 apabila ia dibangunkan.

Pemangku Pengarah Urusannya, Mohamed Iqbal Abdul Rahman, berkata kumpulan telah membentangkan kepada Majlis Sains Negara mengenai pelan, kapasiti dan keupayaannya untuk tujuan berkenaan.

"Ini adalah sebahagian daripada pelan jangka pendek kumpulan untuk menangani keperluan mendesak kepada vaksin COVID-19," katanya.

Menteri Sains, Teknologi dan Inovasi Khairy Jamaluddin sebelum ini berkata, kerajaan bersetuju bahawa kemudahan yang dimiliki oleh Duopharma Biotech Bhd dan Pharmaniaga akan digunakan untuk pembotolan vaksin.

Khairy dilaporkan menjelaskan bahawa kedua-dua syarikat itu dipilih berikutan kedua-duanya berkaitan dengan kerajaan.

Duopharma dimiliki oleh Permodalan Nasional Bhd (PNB) dan Pharmaniaga dimiliki oleh Boustead Holdings Bhd, yang pada masa ini mempunyai kapasiti yang tidak digunakan yang dapat diarahkan untuk tujuan ini.

Mengenai perancangan kumpulan pada masa depan pula, Mohamed Iqbal berkata Pharmaniaga, syarikat farmaseutikal terbesar di Malaysia, dijangka mewujudkan kemudahan vaksin halal pertama di dunia, disasarkan siap pada 2022.

"Pada 2018, Pharmaniaga mengumumkan pelan untuk mendirikan kilang vaksin. Sejak itu, kami telah selesai menjalankan kajian terperinci yang diperlukan dan menjalin kerjasama dengan pengeluar vaksin antarabangsa," katanya.

Selain itu, Pharmaniaga mempunyai pelan jangka panjang untuk pertumbuhan mampan dan menetapkan enam teras strategik untuk memacu syarikat ke peringkat lebih tinggi.

Sebagai syarikat berkaitan kerajaan, Pharmaniaga komited untuk terus memberikan standard perkhidmatan tertinggi untuk membolehkan Kementerian Kesihatan memberi tumpuan kepada penyampaian penjagaan kesihatan, dengan Pharmaniaga sebagai rakan logistik pilihannya.
- BERNAMA

SUPER- going into the Q1, has already got a RM120 mil head start. Estimated PAT for Q1 should easily be RM800+120- RM920.

OIC thats explains why you are so Anti Gloves
Moral of the storey- Never borrow from Ah Long and Gamble in Bursa.- You may run the risk of being gelded.
-----------------------------------------
@ stockraider-Today i becamme a bit mad because ah long came pouring red paint on my house for my contra losses playing gloves last week.Last nite one yourng 20 years old ah long THUGS ASK my wife to hisap his guguchio.

Why is the ‘anti-vaxxer’ movement growing during a pandemic?
-------------------------------------------------
Most Americans fears the development of a vaccine for coronavirus is being dangerously rushed, in part to improve Donald Trump’s prospects ahead of the presidential election in November.

“This situation is different, because of the politics that have been injected into the process and the speed at which they’re developing the vaccines,” says Ms McVay, a communications consultant from California and a supporter of the Democratic party. “Frankly, I don’t trust this president. It just gives me pause.” 


Source- David Crow in New York and Kiran Stacey in Washington AUGUST 20 2020

Annual vaccination requires Billions of gloves
-------------------------------------------
Coronavirus will be around “for ever” and people are likely to need regular vaccinations against it, a former chief scientific adviser to the UK government has said. Prof Mark Walport, a member of the Scientific Advisory Group for Emergencies (Sage), likened the virus to influenza, as he said repeat inoculations on a global scale would almost certainly be required to control it.

He told BBC Radio 4’s Today programme coronavirus was not “going to be a disease like smallpox which could be eradicated by vaccination”.

@Stockraider, you will be lucky if the Goreng stocks get the chance to make LABELS for the vaccine bottles. By the way profits from making labels is around 2 cents per label if I'm not mistaken. Multiply this by 30 million. WOW absolutely lucrative ya ! LOL.

Invest in GLOVES stockraider, don't waste your time spamming. If the BIG 4 is too expensive for you, try AT Sys Bhd if you love penny stocks. They also deal with gloves - Industrial gloves apparently.

@ iswara, Easily RM800 million PAT for the next Quarter.

The chairman of TG mentioned that TG has 26% of the worlds market share of examination Gloves. However he estimates that there is still an acute shortage of gloves even if there is an additional 100 b pieces of gloves over the next 3 years. TG annual production is 82 b. pieces.

Judging by his comments there is a considerable up side in ASP for gloves going forward.

Supermax with its unique business model- (factory to end user) is set to capitalise on this.

Here is another interesting article -

Russia COVID-19 vaccine roll-out plan prompts virus mutation worries.
https://www.channelnewsasia.com/news/world/covid-19-russia-vaccine-plan-virus-mutation-worries-13042310

Interesting article on the China Vaccine.

https://www.orientaldaily.com.my/news/international/2020/08/21/358925

Pharmaniaga TP upped as co deemed frontrunner in Covid-19 vaccine race
TheEdge Fri, Aug 21, 2020 02:53pm - 23 hours ago


KUALA LUMPUR (Aug 21): MIDF Amanah Investment Bank Bhd and Kenanga Investment Bank Bhd are among research firms which had today raised their share target prices (TPs) for Pharmaniaga Bhd in anticipation of earnings growth as the company is seen as the frontrunner to secure the Malaysian government's contract to repackage and distribute the Covid-19 vaccine.

MIDF said today it had revised its Pharmaniaga TP to RM4.74 from the previously-estimated RM3.15. Kenanga said its Pharmaniaga TP is raised to RM1.80 from RM1.35.

Solution & Titijaya can Bungkus- or rather Ta Pau- Pump & Dump Stocks.
---------------------------------
Pharmaniaga - D Pharma are the frontrunners. MOH will decide on the company not China.


Pharmaniaga TP upped as co deemed frontrunner in Covid-19 vaccine race
TheEdge Fri, Aug 21, 2020 02:53pm - 23 hours ago


KUALA LUMPUR (Aug 21): MIDF Amanah Investment Bank Bhd and Kenanga Investment Bank Bhd are among research firms which had today raised their share target prices (TPs) for Pharmaniaga Bhd in anticipation of earnings growth as the company is seen as the frontrunner to secure the Malaysian government's contract to repackage and distribute the Covid-19 vaccine.

MIDF said today it had revised its Pharmaniaga TP to RM4.74 from the previously-estimated RM3.15. Kenanga said its Pharmaniaga TP is raised to RM1.80 from RM1.35.

----------------------------------------------
Posted by stockraider > Aug 22, 2020 1:38 PM | Report Abuse

List of vaccine players; - the dreamers.

1.Top number 1 Cansino with Solution as Distributor Nov vaccine available

2. Sinopharm with Titijaya as distributor { about 2 mths behind cansino}

Solution & Titijaya can Bungkus- or rather Ta Pau- Pump & Dump Stocks.
---------------------------------
Pharmaniaga - D Pharma are the frontrunners. MOH will decide on the company not China.


Pharmaniaga TP upped as co deemed frontrunner in Covid-19 vaccine race
TheEdge Fri, Aug 21, 2020 02:53pm - 23 hours ago


KUALA LUMPUR (Aug 21): MIDF Amanah Investment Bank Bhd and Kenanga Investment Bank Bhd are among research firms which had today raised their share target prices (TPs) for Pharmaniaga Bhd in anticipation of earnings growth as the company is seen as the frontrunner to secure the Malaysian government's contract to repackage and distribute the Covid-19 vaccine.

MIDF said today it had revised its Pharmaniaga TP to RM4.74 from the previously-estimated RM3.15. Kenanga said its Pharmaniaga TP is raised to RM1.80 from RM1.35.

----------------------------------------------
Posted by stockraider > Aug 22, 2020 1:38 PM | Report Abuse

List of vaccine players; - the dreamers.

1.Top number 1 Cansino with Solution as Distributor Nov vaccine available

2. Sinopharm with Titijaya as distributor { about 2 mths behind cansino}

Yes, after bonus issue can reach RM18-00

Every RM Supermax makes now and reinvested on capacity expansion, would generate 2-3 times more RM than PEERs. Market has not yet to realise this explosive growth potential of Supermax. This is the hidden power of OBM -X margin.

REVALUATION

Current Market Capitalisation.

SUPERMAX RM 21.40 = 29 BIL
HARTALEGA RM17.20 = 59BIL
TOPGLOVE RM 28.00 = 76 BIL

To fetch a higher market cap comparable to Topglove(39% now) and Harta(48% now),supermax need-

1. Comparable profitabilty and margin to Topglove , Harta.(70% to 90%of their current profit)

2. Comparable dividend payout policy.

3. Comparable liquidity.

4. Comparable size and production capacity.

5. Better appreciation of OBM-X advantage.

We see more attention and value appreciation in progress now.
All skepticism will be crushed with bumper profit of 800m - 1bil coming profit in QTR 1.
.
Source- Freetospeak CIA analyst.

Phase 3 clinical test for a SAFE vaccine will have to undergo at leat 15 month to 2 years to determine its EFFICACY as per US FDA and WHO guidelines.

Cutting corners to speed up the process will be harmful as the side effects may even bring death.

A rushed vaccine is only to satisfy a hidden agenda - usually political as in China , USA & Russia.

Average Selling Price of All Gloves Soar as Demand Increases!
--------------------------------------------------------
Publish date: Wed, 19 Aug 2020, 6:47 PM

The demand of gloves has surged due to Covid-19 pandemic. There are many companies take advantage of this opportunity to enter into the glove market. However, it is not easy for a small business startup to sustain in this business competitive environment after the outbreak. Therefore, the industry layout will not have large impacts in the long run.

Top Glove’s Average Selling Price (ASP) has rose 20% - 40% in August and September, and the company expects to pay a higher final dividend. However, the average selling price of gloves have gone up due to increase in the market demand. Therefore, Top Glove held a special shareholder’s meeting (EGM) on 18 August 2020 for a 2 for 1 bonus issue.

@ cjp74132. Fully agree and well said- A real pain in the Butt this rr88. This egotistical dude loves spewing garbage here all of the time shamelessly.
---------------------------------------
One of the dumbest postings from this guy (rr88), who must be suffering from altitude sickness in the Alps and/or dementia !!

A mindless trader and self-proclaimed chartist who pays little or no regard to the underlying business, he will speculate wildly, particularly with penny dreadful stocks. In this quest, he comes to this forum to try to get cashed up investors - with nonsensical chart-based predictions - to put some of their wealth in these stocks to help build some momentum for his trading activities.

He's no Nostradamus, as evidenced from his numerous failed predictions. He also unwittingly puts the spotlight on the public scorn for his inflated ego by parading like the naked emperor, ever wondering why the masses don't appreciate the "robes he's wearing"

MOATS- SUPERMAX- A CASE STUDY.

A moat is obviously the water around a castle but in investing terms, a moat is the durable COMPETITIVE ADVANTAGE that a company has that PROTECTS it from being attacked by competitors.

There are five kinds of moats: brand, secret, toll or toll bridge, switching, and price.

1) Brand Moat

SUPER has developed and marketed its own brand namely Aurelia & Maxtor Brand. A brand moat is healthcare and is a huge area for brand building and SUPER is brilliant at it. They build healthcare awareness around it culture especially during the Covid pandemic.

2) Secrets Moat

The second of the five moats is a secrets moat. SUPER is brilliant at creating products around healthcare that they then patent and turn into products especially in the production of Nitrile gloves of the highest quality. SUPER is an established OBM manufacturer.

3) Toll Bridge Moat

SUPER odes not have this which is in essentially a monopoly.

4) Switching Moat

Switching is the cost of shifting from one supplier or product to another. SUPER may be able to do this in future as it may source from other manufacturers. Since the Aurelia brand is strong it may source from other manufacturers to produce the Aurelia brand on a OEM basis.

5) Price Moat

The fifth moat is the price moat. SUPER of course is the king of price moats which is due to its unique business model -OBM. SUPER can create products, distributes and sells products to the end user in strategic locations or rather centres over the world.

CONCLUSION

You might notice that a lot of companies have multiple moats. Certainly, you can have multiple moats, the more the better.

Scorecard for SUPER - 3 out of 5 moats which is considered EXCELLENT.

WHO warns coronavirus vaccine alone won’t end pandemic.
-------------------------------------------------------
‘We cannot go back to the way things were’

CNBC-21st August 2020.

KEY POINTS

1-World leaders and the public must learn to manage the virus and make permanent adjustments to their daily lives to bring the virus down to low levels, the WHO said.

2-Throughout history, outbreaks and pandemics have changed economies and societies, the agency said.

https://klse.i3investor.com/blogs/freetospeak/2020-08-21-story-h151242

https://klse.i3investor.com/blogs/freetospeak/2020-08-21-story-h151242

https://klse.i3investor.com/blogs/freetospeak/2020-08-21-story-h151242

https://klse.i3investor.com/blogs/freetospeak/2020-08-21-story-h151242

https://klse.i3investor.com/blogs/freetospeak/2020-08-21-story-h151242

Another excellent analysis brought to you by CIA-Freetospeak consortium.

Net margin of 38% - the new normal for SUPERMAX post COVID - eye popping and jaw dropping margins - Yes, you reap what you sow some 12-15 years ago by founder DSST.
The OBM-X business model- from factory to end user = SUPER profit margin.

Supermax is a truly world class company. The pride of Malaysia.

Net margin of 38% - the new normal for SUPERMAX post COVID - eye popping and jaw dropping margins - Yes, you reap what you sow some 12-15 years ago by founder DSST.
The OBM-X business model- from factory to end user = SUPER profit margin.
Supermax is a truly world class company. The pride of Malaysia.

Another excellent analysis brought to you by CIA-Freetospeak consortium.

Fantastic closing - RM21.90 powered by the rocketeer- Team Rocket.

TeamRocket is so hilarious. Whatever it is he need to be gelded for better performance as a trader. Anyway thanks for the entertainment TR.

@Team Rocket, whenever u say sell, the OPPOSITE HAPPENS strong buying interest immediately surfaces. LOL.

Keep it up Teamrocket !

@ parrot- Correct. Fully agree with you. Find decision is always up to the individual to suit their risk appetite and investment timeframe. cheers bro.!

SMART Investors Not Willing To Sell Before Bonus Issue Going Ex On 4th September.
------------------------------------------------------------------------

SUPERMAX bonus issue of 1 for 1 will go ex on the 4th September.

Compelling reasons why you should HOLD Supermax -

1- 1st September - Supermax will be included in the prestigious MCSI Global Index.

2- Price is expected reach RM28-00 to RM30-00 before going ex.

3- Assuming closing at RM30 b4 ex- the adjusted price will be RM15-00.

4- Next Quarter PAT is widely estimated at RM800 mil.

As per WHO pandemic is set to stay with us a for a long time. Covid cases on the uptrend.

Less volatility will be seen in the run up to BI.

Trade with caution.

For genuine investors -Accumulate.

.

Its about earnings growth potential and outlook that matters - my friend.

Banks.......Provisioning will leave them impotent for the next few years.

TNB..........boring and run by dinosaurs and flat earnings.
------------------------------------------------------------

Posted by tmi2020 > Aug 21, 2020 10:50 AM | Report Abuse

many still believe glove factory can surpassing Public Bank and Tenaga?

You all will learn your lesson.

@kimsui, you are so cute. Its MSCI not MISC. Yup , FF will sarpu this counter. Well hope they do.
--------------------

Posted by kimsui7364 > Aug 21, 2020 10:32 AM | Report Abuse

After 31-Aug-20 SuperX is on MISC board then all foreign fund will come in to sarpu this counter. The share price will up soon.

SMART Investors Not Willing To Sell Before Bonus Issue Going Ex On 4th September.
------------------------------------------------------------------------

SUPERMAX bonus issue of 1 for 1 will go ex on the 4th September.

Compelling reasons why you should HOLD Supermax -

1- 1st September - Supermax will be included in the prestigious MCSI Global Index.

2- Price is expected reach RM28-00 to RM30-00 before going ex.

3- Assuming closing at RM30 b4 ex- the adjusted price will be RM15-00.

4- Next Quarter PAT is widely estimated at RM800 mil.

As per WHO pandemic is set to stay with us a for a long time.

.

Correct, sell sell sell Parma stocks and channel to gloves.

FDs are beings channelled to investments in Glove counters.- Interesting..
----------------------------
The bull run is being financed by cash due to a reallocation from term deposits, which are now giving a lower rate of return due to the dip in interest rates this year, according to the stock exchange operator.

“Lower interest fixed deposit rates have released new liquidity into the market, ” Bursa Malaysia CEO Datuk Muhamad Umar Swift reportedly said.

This reflects confidence in the Healthcare sector particularly the Top 6 glove counters. -TG, SUPER, HARTA, KOSSAN, COMFORT & CAREPLUS.

And rightly so as exponential earnings is assured for at least the next 6 quarters- looking tat the severity of this pandemic- which is set to stay with us for a long time.

Best bets - TG & SUPER.

Gloves are certainly not a Bubble
-------------------------------
SUPERMAX price is well supported by earnings- PAT of RM 400 mil for Q4, and a projected RM800 mil for the next quater and RM 1 billion for the next.

A bubble is where stock is selling on concept & hype with no concrete earnings to show.

Hope you are don't mislead the people here.

SUPERMX Profit Margin is Astonishing 44% !!!
--------------------------------

This is the awesome power of Own Brand Manufacturing and Distribution- yes, the only business model that can give you such amazing margins.

DS Stanleys Thai's brainchild- OBM- took 10 -12 years to establish this global network- and finally reaping the rewards with the pandemic. The beauty is that the ASP can be easily raised if demand is overwhelmingly.

That's why SUPERMAX is the King Of Gloves.

FDA- Guidelines on Phase 3 clinical trials.

Phase 3: Just 33% of drugs make it past Phase 2 and into Phase 3, which tests the potential treatment in the largest number of people. This phase measures both safety and effectiveness with many volunteers, sometimes thousands. Phase 3 trials last from one to four years.

FDA Approval: Approximately 25 to 30% of treatments move forward in the approvals process. After Phase 3, a pharmaceutical company may submit a New Drug Application (NDA) for the treatment to the Food and Drug Administration (FDA). The FDA then reviews results from all stages of the trial to determine whether it will approve the drug and allow the pharmaceutical company to begin marketing it to the public.

Phase 4: Phase 4 is often called “Post-Approval Research and Monitoring.” After a new treatment is approved by the FDA, the pharmaceutical or device company may want to continue monitoring patients to learn more about the treatment’s longer-term effects, while comparing it against other already-approved options. It may take time for long-term side effects to appear, making this an important phase.

Phase 3 mass testing will usually take 9 month to 12 months to conclude its efficacy. Hope all will be fine without much setbacks.

TWINDEMIC - Another Shot In The Arms For Gloves/PPE's

NYT. As public health officials look to fall and winter, the specter of a new surge of Covid-19 gives them chills. But there is a scenario they dread even more: a severe flu season, resulting in a “twindemic.”

The magazine said, Even a mild flu season could stagger hospitals already coping with Covid-19 cases. And though officials don’t know yet what degree of severity to anticipate this year, they are worried large numbers of people could forgo flu shots, increasing the risk of widespread outbreaks.

The concern about a twindemic is so great that officials around the world are pushing the flu shot even before it becomes available in clinics and doctors’ offices.

It quoted Dr. Robert Redfield, director of the U.S. Centers for Disease Control and Prevention has been talking it up, urging corporate leaders to figure out ways to inoculate employees. The C.D.C. usually purchases 500,000 doses for uninsured adults but this year ordered an additional 9.3 million doses.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has been imploring people to get the flu shot, “so that you could at least blunt the effect of one of those two potential respiratory infections.”

TWINDEMIC_- Another Shot In The Arms For Gloves/PPE's

NYT. As public health officials look to fall and winter, the specter of a new surge of Covid-19 gives them chills. But there is a scenario they dread even more: a severe flu season, resulting in a “twindemic.”

The magazine said, Even a mild flu season could stagger hospitals already coping with Covid-19 cases. And though officials don’t know yet what degree of severity to anticipate this year, they are worried large numbers of people could forgo flu shots, increasing the risk of widespread outbreaks.

The concern about a twindemic is so great that officials around the world are pushing the flu shot even before it becomes available in clinics and doctors’ offices.

It quoted Dr. Robert Redfield, director of the U.S. Centers for Disease Control and Prevention has been talking it up, urging corporate leaders to figure out ways to inoculate employees. The C.D.C. usually purchases 500,000 doses for uninsured adults but this year ordered an additional 9.3 million doses.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has been imploring people to get the flu shot, “so that you could at least blunt the effect of one of those two potential respiratory infections.”

Malaysia Rubber Gloves Shortages Continue to Support Earnings
---------------------------------------------------
Author: kltrader | Publish date: Wed, 19 Aug 2020,

With the recent vaccine news, investors are concerned about what this means for glove demand. Macquarie Equities Research (MQ Research) said the US FDA indicated shortages of medical gloves in the U.S., suggesting demand and average selling price (ASP) trend to remain buoyant in the near term. MQ Research believes the recent pullback in share prices is an opportunity to ACCUMULATE.